Beta-Thalassemia
Showing 1 - 25 of 60
Beta-Thalassemia Trial (CS-101 injection)
Not yet recruiting
- Beta-Thalassemia
- CS-101 injection
- (no location specified)
Sep 27, 2023
Beta-Thalassemia Trial in Nanning (CS-101)
Recruiting
- Beta-Thalassemia
- CS-101
-
Nanning, ChinaThe First Affiliated Hospital of Guangxi Medical University
Sep 9, 2023
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Nashville (CTX001)
Recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Nashville, Tennessee
- +5 more
Feb 2, 2023
MDS (MDS), Beta-thalassemia, Myeloproliferative Tumor(MPN)-Associated Myelofibrosis Trial in Worldwide (Luspatercept)
Recruiting
- Myelodysplastic Syndromes (MDS)
- +2 more
-
Los Angeles, California
- +203 more
Jan 30, 2023
The Prevelence of HBB c.93-21 G-A in ß Thalassemia Patients
Recruiting
- Beta-Thalassemia
- ARMS PCR
-
Assiut, EgyptFaculty of Medicine Assiut University
Jan 30, 2023
A Single-Site Tissue Repository Providing Annotated Biospecimens
Recruiting
- Age-Related Macular Degeneration
- +46 more
- Specimen sample
-
Waltham, MassachusettsSanguine Biosciences
Nov 22, 2022
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)
Active, not recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Stanford, California
- +11 more
Nov 30, 2022
A Long-term Follow-up Study in Subjects Who Received CTX001
Enrolling by invitation
- Beta-Thalassemia
- +6 more
- CTX001
-
New York, New York
- +12 more
Nov 18, 2022
Beta-Thalassemia Trial in Bulgaria, Israel, United States (VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID)
Withdrawn
- Beta-Thalassemia
- VIT-2763 60 mg QD
- +3 more
-
Whittier, California
- +6 more
Nov 7, 2022
Sickle Cell Disease, Sickle Cell Trait, Beta-Thalassemia Trial (High performance liquid chromatography, Automated sickling test,
Not yet recruiting
- Sickle Cell Disease
- +4 more
- High performance liquid chromatography
- +5 more
- (no location specified)
Aug 17, 2022
Minimisation Measures for REBLOZYL Among Healthcare
Active, not recruiting
- Myelodysplastic Syndromes
- Beta-thalassemia
-
City, State, AustriaLocal Institution
Aug 4, 2022
Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)
Not yet recruiting
- Beta-Thalassemia
- +6 more
- CTX001
- (no location specified)
Jul 26, 2022
Cognitive Function, Fatigue and Health Related Quality of Life
Recruiting
- Cognitive Change
- +3 more
-
Giza, EgyptAbo El-Rish Pediatric Hospital
Jul 20, 2022
The Prevelence of IVS 1-6 [HBB:c.92 +6 T-C] Gene Mutation in
Not yet recruiting
- Beta-Thalassemia
- ARMS
- (no location specified)
May 10, 2022
Beta-Thalassemia Trial in Worldwide (LentiGlobin BB305 Drug Product)
Active, not recruiting
- Beta-Thalassemia
- LentiGlobin BB305 Drug Product
-
Oakland, California
- +8 more
Feb 4, 2022
Erythrocyte Transfusion, Beta-Thalassemia Trial in Worldwide (Luspatercept, Placebo)
Completed
- Erythrocyte Transfusion
- Beta-Thalassemia
- Luspatercept
- Placebo
-
Los Angeles, California
- +72 more
Jan 21, 2022
Beta-Thalassemia Trial in Ferrara, Firenze, Pisa (Sirolimus 0.5 mg)
Recruiting
- Beta-Thalassemia
- Sirolimus 0.5 mg
-
Ferrara, FE, Italy
- +3 more
Nov 11, 2021
Iron Status in BTM With Blood Transfusion
Not yet recruiting
- Beta-Thalassemia
- (no location specified)
Jul 13, 2021
Transfusional Iron Overload, Beta-Thalassemia Trial in Worldwide (SPD602)
Terminated
- Transfusional Iron Overload
- Beta-Thalassemia
-
Boston, Massachusetts
- +8 more
Jun 10, 2021
Beta-thalassemia, Iron Overload Trial in Los Angeles, Oakland, Chicago (Deferasirox)
Completed
- Beta-thalassemia
- Iron Overload
-
Los Angeles, California
- +2 more
Jun 8, 2021
Transfusional Iron Overload, Beta-thalassemia Trial in Worldwide (SPD602 (FBS0701, SSP-004184))
Completed
- Transfusional Iron Overload
- Beta-thalassemia
- SPD602 (FBS0701, SSP-004184)
-
Oakland, California
- +8 more
May 30, 2021
Transfusional Iron Overload, Iron Overload, Iron Chelation Trial (SPD602, Deferasirox)
Withdrawn
- Transfusional Iron Overload
- +6 more
- (no location specified)
Jun 1, 2021